Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives Average Recommendation of “Buy” from Analysts

Shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have received an average recommendation of “Buy” from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $12.7692.

TSHA has been the subject of a number of research reports. Pivotal Research set a $14.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, June 23rd. Citizens Jmp reiterated a “market outperform” rating and set a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. BMO Capital Markets increased their price objective on shares of Taysha Gene Therapies from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 23rd. Needham & Company LLC restated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Tuesday, June 23rd.

Taysha Gene Therapies Price Performance

Shares of TSHA opened at $5.02 on Friday. The firm has a market cap of $1.64 billion, a PE ratio of -11.95 and a beta of 1.19. Taysha Gene Therapies has a 52-week low of $2.71 and a 52-week high of $7.30. The business’s 50 day moving average price is $5.93 and its two-hundred day moving average price is $5.65. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.76 and a current ratio of 17.76.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, equities analysts anticipate that Taysha Gene Therapies will post -0.52 EPS for the current year.

Insider Buying and Selling

In other news, insider Sukumar Nagendran sold 200,000 shares of the business’s stock in a transaction that occurred on Friday, July 10th. The stock was sold at an average price of $6.24, for a total transaction of $1,248,000.00. Following the completion of the sale, the insider owned 936,410 shares in the company, valued at $5,843,198.40. The trade was a 17.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.48% of the company’s stock.

Institutional Trading of Taysha Gene Therapies

Hedge funds have recently bought and sold shares of the business. Engineers Gate Manager LP acquired a new position in Taysha Gene Therapies during the second quarter worth $709,000. Squarepoint Ops LLC raised its holdings in shares of Taysha Gene Therapies by 38.8% in the 2nd quarter. Squarepoint Ops LLC now owns 569,269 shares of the company’s stock worth $3,877,000 after acquiring an additional 158,987 shares during the last quarter. Arizona State Retirement System raised its holdings in shares of Taysha Gene Therapies by 5.4% in the 2nd quarter. Arizona State Retirement System now owns 39,633 shares of the company’s stock worth $270,000 after acquiring an additional 2,014 shares during the last quarter. California State Teachers Retirement System raised its holdings in shares of Taysha Gene Therapies by 742.3% in the 2nd quarter. California State Teachers Retirement System now owns 1,153,437 shares of the company’s stock worth $7,855,000 after acquiring an additional 1,016,504 shares during the last quarter. Finally, Seven Fleet Capital Management LP lifted its position in Taysha Gene Therapies by 140.4% in the 2nd quarter. Seven Fleet Capital Management LP now owns 1,504,400 shares of the company’s stock valued at $9,940,000 after acquiring an additional 878,692 shares in the last quarter. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.